Today, the American Pain Society tried to make it clear to the FDA that while reducing/eliminating deaths related to narcotic pain medication is a noble goal, they are very concerned that in all practicality, this effort will result in increased pain for the living. The FDA is now requiring manufacturers of 24 short and long acting opioid pain medications to come up with a better plan for managing the risk of death for their customers. This program, called REMS (Risk Evaluation and Mitigation Strategy), is meant to insure that the risks of the drugs outweigh the benefits.

Similar posts: elavil medication